Rapid Tests Market Report 2025

The rapid tests market size has grown rapidly in recent years. It will grow from $31.07 billion in 2024 to $34.67 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth during the historical period was fueled by an increasing occurrence of infectious diseases, heightened demand for diagnostics at the point of care, a growing emphasis on early detection, and a rising need for fast and precise test results, supported by enhanced healthcare expenditure and improved access.

The rapid tests market size is expected to see rapid growth in the next few years. It will grow to $53.17 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. Factors contributing to this future growth include the rising usage of at-home testing kits, growing attention toward personalized healthcare, increasing demand for rapid diagnostics in developing countries, and broader application of these tests beyond traditional clinical settings. Key emerging trends include the evolution of microfluidic platforms, improved integration of biosensors in testing kits, advancements in multiplex testing systems, the application of artificial intelligence (AI) in diagnostic procedures, and innovations in portable diagnostic equipment.

The growing number of infectious disease cases is contributing to the expansion of the rapid tests market. These diseases, caused by harmful organisms such as bacteria, viruses, fungi, or parasites, are easily transmitted between individuals. Increasing global mobility contributes to the faster spread of such pathogens. Rapid testing solutions play a critical role by providing accurate and timely diagnoses at the point of care, allowing healthcare providers to initiate treatment and containment measures promptly. They play an essential role in reducing diagnostic delays, enhancing disease response efforts, and curbing infection transmission. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased by 10.7%, rising from 4,380 cases in 2022 to 4,850 in 2023. This trend underscores how the rise in infectious diseases is accelerating the growth of the rapid tests market.

Leading companies in the rapid tests market are developing high-tech solutions like bioluminescence-based technologies that allow for quicker and more sensitive microbial detection. These advanced techniques use biochemical reactions that emit light, generally involving luciferase enzymes and specific substrates, to identify microorganisms or biological indicators. For instance, in March 2025, Nelson Labs, a US-based provider of testing services, introduced a rapid sterility testing method. This approach shortens the traditional 14-day incubation time to just six days using bioluminescence to detect microbial ATP - an indicator of living organisms - by capturing the emitted light during the reaction. The system automates microbial contamination detection, boosts testing precision, ensures compliance with regulations, and allows for quicker product release without compromising safety.

In June 2023, Avacta Group plc, a UK-based life sciences firm, completed the acquisition of Coris Bioconcept SRL for $13.21 million (£10.4 million). This acquisition allowed Avacta to broaden its footprint in the rapid diagnostics sector, enhance its capabilities in in vitro diagnostics (IVD), and leverage Coris’s well-established portfolio of lateral flow tests and its international distribution channels. Coris Bioconcept SRL is a Belgium-based company specializing in the development and supply of rapid diagnostic tests.

Major players in the rapid tests market are Pfizer Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers, BioMérieux SA, Quidel Corporation, Bio‑Rad Laboratories Inc., PerkinElmer Inc., OraSure Technologies Inc., SEKISUI Diagnostics LLC, Trivitron Healthcare Pvt. Ltd., Ellume Limited, Access Bio Inc., ACON Laboratories Inc., CTK Biotech Inc., iHealth Labs Inc., Wondfo USA Co. Ltd., InBios International Inc., Lab Care Diagnostics India Pvt. Ltd., Immunostics Inc., Aptitude Medical Systems Inc., Nano-Ditech Corporation, Azure Biotech Inc., Beijing Hotgen Biotech Co. Ltd., CorDx Inc., Genabio Diagnostics Inc., Maxim Biomedical Inc., OSANG LLC, and Watmind USA.

North America was the largest region in the rapid tests market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rapid tests report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rapid tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rapid tests market consists of revenues earned by entities by providing services such as point-of-care diagnostics, on-site screening, home-based testing, mobile health testing units, and diagnostic support for early disease detection and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The rapid tests market also includes sales of rapid diagnostic kits, test strips, reagents, lateral flow assays, analyzers, and related consumables used for the detection of various diseases and conditions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The rapid tests market research report is one of a series of new reports that provides rapid tests market statistics, including the rapid tests industry global market size, regional shares, competitors with the rapid tests market share, detailed rapid tests market segments, market trends, and opportunities, and any further data you may need to thrive in the rapid tests industry. This rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Rapid tests are diagnostic tools used for the quick detection of specific diseases or conditions, often delivering results within minutes to an hour. These tests do not require complex laboratory infrastructure, making them convenient and accessible. They are user-friendly, need minimal equipment, and can be administered at the point of care - such as clinics, pharmacies, or even at home. The primary function of rapid tests is to support immediate diagnostic decisions, enabling prompt treatment and aiding in disease control.

The main categories of rapid tests include instruments, consumables, and others. Instruments are devices used to analyze samples and encompass portable analyzers, benchtop analyzers, handheld devices, scanners or readers, and multiplex analyzers. These instruments are used to detect contaminants like pathogens, allergens, meat speciation, and pesticides, utilizing various technological methods such as polymerase chain reaction (PCR), immunoassay-based techniques, chromatography-based approaches, and spectroscopy-based tools. Rapid tests are widely used in cardiology, oncology, pregnancy and fertility, toxicology, glucose monitoring, infectious diseases, and more. The major end users of these tests include hospitals and clinics, diagnostic labs, home care settings, and other healthcare environments.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.